Table of Content
- 1. Executive Summary
- 2. Industry Introduction Taxonomy Market Definition
- 3. Market Trends and Success Factors Macro-economic Factors Market Dynamics Recent Industry Developments
- 4. Global Market Demand Analysis 2019 to 2023 and Forecast 2024 to 2034 Historical Analysis Future Projections
- 5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034
- 5.1. Product Type
- 5.2. Technology
- 5.3. Application
- 5.4. Diagnostic Laboratories
- 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Product Type
- 6.1. Kits and Assays
- 6.1.1. cfDNA Isolation Kits
- 6.1.2. Mutation-Specific Assays
- 6.2. Instruments
- 6.2.1. Sequencers
- 6.2.2. PCR Machines
- 6.3. Bioinformatics Tools
- 6.3.1. Mutation Detection Algorithms
- 6.3.2. Cloud-Based Analytics Platforms
- 6.4. Service Models
- 6.4.1. Diagnostic Labs
- 6.4.2. Outsourced Analysis Services
- 6.1. Kits and Assays
- 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Technology
- 7.1. Next-Generation Sequencing (NGS)
- 7.2. Polymerase Chain Reaction (PCR)
- 7.3. Microarrays and Hybridization-Based Assays
- 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Application
- 8.1. Oncology
- 8.1.1. Cancer Screening
- 8.1.2. Therapy Monitoring
- 8.1.3. Minimal Residual Disease (MRD) Detection
- 8.1.4. Tumor Mutational Burden (TMB)
- 8.2. Prenatal Testing
- 8.2.1. Non-Invasive Prenatal Testing (NIPT)
- 8.2.2. Pregnancy Complications
- 8.3. Organ Transplantation
- 8.4. Other Applications
- 8.4.1. Infectious Disease Diagnostics
- 8.4.2. Neurodegenerative Disease Research
- 8.1. Oncology
- 9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Diagnostic Laboratories
- 9.1. Diagnostic Laboratories
- 9.1.1. Tier 1 Global Labs
- 9.1.2. Specialty Oncology Labs
- 9.2. Hospitals and Clinics
- 9.2.1. Academic Medical Centers
- 9.2.2. Community Hospitals with cfDNA as part of routine panels
- 9.3. Research Institutions
- 9.3.1. Cancer Genome Projects
- 9.3.2. Universities with cfDNA innovation centers
- 9.4. Biopharma
- 9.4.1. Companion Diagnostics (CDx)
- 9.4.2. Drug Efficacy Trials
- 9.1. Diagnostic Laboratories
- 10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region
- 10.1. North America
- 10.2. Latin America
- 10.3. Western Europe
- 10.4. Eastern Europe
- 10.5. East Asia
- 10.6. South Asia & Pacific
- 10.7. MEA
- 11. North America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, By Key Segments and Countries
- 12. Latin America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, By Key Segments and Countries
- 13. Western Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, By Key Segments and Countries
- 14. Eastern Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, By Key Segments and Countries
- 15. East Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, By Key Segments and Countries
- 16. South Asia & Pacific Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, By Key Segments and Countries
- 17. MEA Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, By Key Segments and Countries
- 18. Sales Forecast 2024 to 2034 By Product Type, Technology, Application, and Diagnostic Laboratories for 30 Countries
- 19. Competition Outlook Market Structure Analysis Company Share Analysis by Key Players Competition Dashboard
- 20. Company Profile
- 20.1. Illumina, Inc.
- 20.2. Natera, Inc.
- 20.3. Guardant Health, Inc.
- 20.4. Freenome Holdings, Inc.
- 20.5. GRAIL, Inc.
- 20.6. Exact Sciences Corporation
- 20.7. Foundation Medicine, Inc.
- 20.8. Biocept, Inc.
- 20.9. Thermo Fisher Scientific Inc.
- 20.10. Roche Diagnostics
- 20.11. Agilent Technologies, Inc.
- 20.12. Quest Diagnostics Incorporated
- 20.13. Laboratory Corporation of America Holdings (LabCorp)
- 20.14. Myriad Genetics, Inc.
- 20.15. BillionToOne, Inc.
